Dr. Foxpaws Fauxpas
@foxpaws_onco
Clinical Oncologist, perpetual student, quizzer & digital artist. Interests: GI, Gyn, GU, Breast, Lung, hemonc, CNS & pall onc. Alumnus of JIPMER, Pondicherry.
Adjuvant therapies in Pancreatic Cancer. Folfirinox (PRODIGE24) ✅ OS 54 v 35m ✅ mDFS 21 v 12m Gem Cap (ESPAC4) OS ✅ 28 vs 25m DFS ❌ Gem Nabpacli (APACT) OS ✅ 40 v 36m, DFS ❌ Radiation (LAP07) ❌ What is routinely used in practice? @SuyogCancer @OncBrothers
Excellent paper by @MirghSumeet et al Financial toxicity can be cut to 1% by replacing plerixafor with cyclophosphamide ± bortezomib And keeping the transplant outcomes similar! Practice changing, definitely! @nihardesai89 @Prasshmehta @NicoGagelmann
Just published in @CancerMedicine 15 years of PBSC mobilization experience in Myeloma Even in the CAR-T era, collecting sufficient PBSCs is crucial. - GCSF+plerixafor comparable to chemo mobilization - If prior RT (to hematopoietic sites - spine, pelvis), chemo-mobn is better
It seems almost unjust when you are coping with profound loss to see the world keep turning But there’s sometimes a comfort to be found there too: that life does go on It can be both
The way life goes on after people die is one of the most humbling and scary things in life.
🚨 Who should undergo pancreatic cancer screening? 🤔 #ESMOGI25 ▪️PRSS1 (Hereditary Pancreatitis): RR ~53–87, risk up to 55% ▪️STK11 (Peutz-Jeghers): RR ~132, lifetime risk 11–36% ▪️CDKN2A (FAMMM): RR ~20–40, risk up to 25% ▪️SPINK1, TP53, BRCA1/2, PALB2, ATM, Lynch, FPC: All…
Nitrofurantoin will not work for UTI by Proteus species coz it does not work at an alkaline pH and Proteus has a powerful urease enzyme which coverts urea to ammonia and makes the urine highly alkaline. For same reason,Urine alkalinizers shouldn't be given for Proteus UTI either
Definition of resectable stage III NSCLC: Systematic review (n=70) Only 58% defined “resectable”; 60% excluded N3, 32% multistation N2. 🧮 Proposed: single-station N2, R0 feasible, MDT consensus. lungcancerjournal.info/article/S0169-… @OncoAlert
In this discussion of “Challenging Cases” with @DrCarlaCasulo & #DrTaraGraff, we had a chance to touch on our options in R/R DLBCL: Epcoritamab, Glofitamab, and LoncaT! Here is the table/studies that got these drugs approved. #HemeTwitter #MedTwitter #OncTwitter
🔥New series: “Challenging Cases” from the community. Starting off with treatment options in R/R DLBCL with focus on bi-specific antibodies with @DrCarlaCasulo & #DrTaraGraff Full discussion: ⭐️ oncbrothers.com/cases-dlbcl-20… ⭐️ Also on the “Oncology Brothers” podcast #HemeTwitter
🧪 Updated combined analysis of RTOG 9501 & EORTC 22931 trials This study evaluated the role of post-operative chemoradiation (CRT) vs radiotherapy (RT) alone in 744 patients with head and neck cancer (HNC), with long-term follow-up (median 6.9 years). 📊 Key Findings: •CRT…
Radio- chemotherapy induced oral mucositis - prevention and management doi.org/10.1038/s41368…
Thrilled to see our work on oral metronomic chemotherapy featured by Prof. David Kerr (@UniofOxford) on MEDSCAPE ! 📰 “The Global Applicability of Oral Metronomic Chemotherapy” 🔗 medscape.com/viewarticle/gl… Pushing the boundaries to equitable cancer care! #GlobalOnco @TMC_Varanasi
Even though I've used SG only once and I've never used DatoDxD - as an academic exercise I wanted to review the ADR profile of both ADCs. Made a small infographic card for the same. Hope it is useful for ppl who need it. @OncBrothers @SuyogCancer @PTarantinoMD @dr_yakupergun
Expected pathological complete response rates in early stage II/III HER2+ breast cancer. #bcsm @DFCI_BreastOnc
Therapy for Stage IV NSCLC With (1) & Without (2) Driver Alterations: ASCO Living Guideline, Version 2025.1 1⃣ ascopubs.org/doi/pdf/10.120… 2⃣ ascopubs.org/doi/pdf/10.120…
2/3 🌟 Forest plots of HR between ICI + chemotherapy and/or antiangiogenic therapy and chemotherapy and/or antiangiogenic therapy. 💫 PFS & OS 💫 Stratified by chemotherapeutic agents --- Pemetrexed and Paclitaxel
A ₹9,000 job in India comes with an attendance app A ₹9,000 crore project doesn’t publish audited reports Scrutiny is for the powerless Freedom is for the connected Still think accountability is universal?
Just published in @ASCOPost My reflections from ICML 2025 — where lymphoma history met its future. From COO giving way to molecular clusters, to the TME guiding CART outcomes, to the undeniable momentum in aggressive B-cell lymphoma 👉 ascopost.com/news/july-2025… #ICML2025 #lymsm
Congratulations! Our ten commandments!
Humbled to share my (very first) primary authored paper: Top 10 Tips for #hpm about #survonc Deeply grateful for my writing mentor @GreggWeltyMD senior author @DrN_CancerPCP wisdom of @DrNicolasHart and colleagues, mentees and friends @doc_martin19 with editorial insight of…
Common Terminology Criteria for Adverse Events (CTCAE) has 26 categories for 837 terms, and 3,185 options when you account for Grade 1 to 5 🤯! I wanted to be able to interactively visualize CTCAE so I some wrote code 🧑💻 @TheCodingDocs Take a look at --> thecodingdocs.com/clincal/ctcae
What is resectable , borderline resectable and unresectable Gall bladder cancer . Nice slide by Dr Gonzalo @myESMO #ESMOGI2025
Babe wake up new update to Wong Baker pain scale just dropped @realbowtiedoc @drmpk91